Working… Menu

Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00061425
Recruitment Status : Completed
First Posted : May 28, 2003
Last Update Posted : January 9, 2009
Information provided by:
Immunomedics, Inc.

Brief Summary:
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

Condition or disease Intervention/treatment Phase
Non-Hodgkin's Lymphoma Lymphoma, B-Cell Drug: radiolabeled epratuzumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG
Study Start Date : August 2000
Actual Primary Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (All histological grades of NHL will be eligible for this trial.)
  • Measureable via CT, with at least one lesion > or = 1.5cm in one or both dimensions. (Splenic tumors in absence of other tumors will not qualify.)
  • Radiological studies (ie - CT) must be performed within 4 weeks prior to study start.
  • Acceptable tumor burden that will allow adequate follow-up and evaluation.
  • Less that 25% bone marrow involvement, determined by bone marrow biopsy.
  • Must observe the following washout periods:

At least 4 weeks beyond any major surgery. At least 4 weeks beyond any radiation therapy to the index lesion, and has recovered from radiation-induced toxicity.

At least 4 weeks beyond chemotherapy and/or immunotherapy. At least 2 weeks beyond corticosteriod(s) use and blood counts are with laboratory criteria.

  • Must have Karnofsky score >70% (or equivalent, ECOG 0-2) with expected survival of at least 6 months.
  • Serum creatinine < or = 1.5mg/dl or creatinine clearance > or = 50ml/min.
  • Serum bilirubin < or = 2mg/dl.
  • Hemoglobin > or = 10 g/dl; WBC > or = 3000/mm3; granulocyte count > or = 150/mm3; platelet count > or = 100,000/mm3 with out transfusions or cytokines for at least 30 days prior to study.
  • Immunomedics ELISA assay of HahLL2 < 100ng/ml for those with prior history of monoclonal antibody infusions.
  • Cognizant informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00061425

Sponsors and Collaborators
Immunomedics, Inc.
Layout table for investigator information
Study Director: William Wegener Immunomedics, Inc.
Layout table for additonal information Identifier: NCT00061425    
Other Study ID Numbers: IM-T-hLL2-06-EU
First Posted: May 28, 2003    Key Record Dates
Last Update Posted: January 9, 2009
Last Verified: January 2009
Keywords provided by Immunomedics, Inc.:
recurrent B-cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents